Eli Lilly to Acquire Ajax Therapeutics in $2.3B Oncology Deal
INDIANAPOLIS, NEW YORK & CAMBRIDGE, Mass., April 27, 2026 Eli Lilly and Company has announced a definitive agreement to...
Clinical Development
Advertisement
Clinuvel Advances Vitiligo Phase 3 with EMA Support
MELBOURNE, Australia & AMSTERDAM, Netherlands, April 24, 2026 Clinuvel Pharmaceuticals Ltd has announced that it has received final Scientific...
Septerna Initiates SEP-479 Phase 1 Hypoparathyroidism
SOUTH SAN FRANCISCO, Calif., April 13, 2026 Septerna, Inc. has announced the initiation of its Phase 1 clinical trial...
Enanta Pharma Advances EDP-978 Phase 1 Urticaria Drug
WATERTOWN, Mass., April 13, 2026 Enanta Pharmaceuticals, Inc. has announced the first participant dosing in its Phase 1 clinical...
Nxera Pharma Advances Schizophrenia Drug to Phase 2
TOKYO, Japan and CAMBRIDGE, UK, April 13, 2026 Nxera Pharma Co., Ltd. announced that its partner Neurocrine Biosciences, Inc....
Advertisements
C4 and Roche Expand DAC Cancer Drug Collaboration
WATERTOWN, Mass., April 09, 2026 C4 Therapeutics, Inc. has announced a major expansion of its long-term collaboration with Roche,...
Phanes Advances Spevatamig to Expansion in BTC Trial
SAN DIEGO, April 7, 2026 Phanes Therapeutics, Inc. has announced the initiation of the dose expansion phase in its...
NanoViricides Files Measles Drug for Rare Disease Status
SHELTON, Connecticut, United States, April 7, 2026 NanoViricides, Inc., a clinical-stage biopharmaceutical company, announced that it has filed an...
Fortitude Advances T-Cell Therapy for Axial Disease
WALTHAM, Massachusetts, United States, April 7, 2026 Fortitude Biomedicines, Inc. announced progress on its lead immunology program, a first-in-class...
Ocugen Completes Dosing in Phase 2/3 Stargardt Trial
MALVERN, Pa., USA — April 1, 2026 Ocugen, Inc. has announced the early completion of dosing in its Phase...
Advertisement
